帕金森氏症藥物市場規模、佔有率、成長分析，按藥物類別、給藥方法、年齡、地區 - 產業預測，2025-2032

2023年帕金森氏症藥物的全球市場規模為46億美元，從2024年的50.9億美元成長到2032年的113.9億美元，預計在預測期間（2025-2032年）將以複合年成長率成長。 10.6%。

全球帕金森氏症藥物市場預計將顯著成長，因為目前有超過 1000 萬人患有這種神經系統疾病，其特徵是多巴胺產生減少以及震顫和僵硬等症狀。隨著這種疾病的盛行率持續上升，對有效症狀管理的需求不斷成長，市場將受益於對聯合治療、緩釋性藥物、基因療法進展和政府資助的興趣的增加。此外，人口老化、醫療保健系統改善以及持續研發等因素正在推動市場發展。品牌藥物的專利到期和強大的新療法研發管線在預測期內為該行業的公司提供了利潤豐厚的機會，進一步增加了市場潛力。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 宏觀經濟指標
• 價值鏈分析
• 價格分析

帕金森氏症藥物市場規模：依藥物類別

• 市場概況
• 脫羧酶抑制劑
• 多巴胺促效劑
• COMT抑制劑
• MAO-B抑制劑
• 其他

帕金森氏症藥物市場規模：依給藥方式分類

• 市場概況
• 口服
• 注射
• 經皮的

帕金森氏症藥物市場規模：依年齡層分類

• 市場概況
• 50歲以下
• 50歲以上

帕金森氏症藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• UCB SA（Belgium）
• GlaxoSmithKline plc（UK）
• Merck & Co., Inc.（USA）
• Boehringer Ingelheim（Germany）
• Lundbeck A/S（Denmark）
• Acadia Pharmaceuticals Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Amneal Pharmaceuticals, Inc.（USA）
• Supernus Pharmaceuticals, Inc.（USA）
• Kyowa Kirin Co., Ltd.（Japan）
• Orion Corporation（Finland）
• Neurocrine Biosciences, Inc.（USA）
• Acorda Therapeutics, Inc.（USA）
• Ipsen SA（France）
• Luye Pharma Group（China）
• NeuroDerm Ltd.（Israel）（acquired by Mitsubishi Tanabe Pharma）
• Revance Therapeutics, Inc.（USA）

結論和建議

Global Parkinson'S Disease Drug Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 5.09 billion in 2024 to USD 11.39 billion by 2032, growing at a CAGR of 10.6% during the forecast period (2025-2032).

The global Parkinson's disease drug market is poised for significant growth, driven by over 10 million individuals currently affected by this neurological disorder, characterized by declining dopamine production and symptoms like tremors and stiffness. As the disease's prevalence rises and the need for effective symptom management continues to grow, the market is benefiting from increased interest in combination therapies, extended-release medications, gene therapy advancements, and supportive government funding. Additionally, factors such as an aging population, improved healthcare systems, and ongoing research and development are bolstering market expansion. The expiration of patents for branded drugs and a strong pipeline of new treatments present lucrative opportunities for industry players during the forecast period, further enhancing the market's potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Parkinson'S Disease Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Parkinson'S Disease Drug Market Segmental Analysis

Global Parkinson'S Disease Drug Market is segmented by drug class, administration, age and region. Based on drug class, the market is segmented into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-b inhibitors and others. Based on administration, the market is segmented into oral, injection and transdermal. Based on age, the market is segmented into < 50 years and > 50 years. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Parkinson'S Disease Drug Market

The global Parkinson's Disease drug market is significantly influenced by several key drivers. Foremost among them is the growing aging population alongside the escalating incidence of Parkinson's disease. As the demographic landscape shifts with an increasing number of elderly individuals, the prevalence of neurological disorders, including Parkinson's, is on the rise. This surge in patient numbers directly correlates with a heightened demand for effective treatment options, thus propelling the market's growth. As a result, this dynamic is anticipated to positively impact the expansion of the Parkinson's Disease drug market worldwide throughout the forecast period.

Restraints in the Global Parkinson'S Disease Drug Market

The global market for Parkinson's disease drugs faces significant restraints primarily due to the high costs associated with treatment. As the prevalence of Parkinson's disease continues to rise, the financial burden on patients, families, and healthcare systems is becoming increasingly pronounced. This economic strain often poses a barrier to accessing necessary treatments and medications, thereby inhibiting the overall growth of the market. Consequently, the prohibitive expense of managing Parkinson's disease is anticipated to serve as a critical challenge for market expansion throughout the forecast period, impacting both patient care and the availability of new therapeutic options.

Market Trends of the Global Parkinson'S Disease Drug Market

The Global Parkinson's Disease Drug market is experiencing substantial growth, driven by a notable surge in research and development funding from both government and corporate sectors aimed at advancing treatment options. This trend is propelling pharmaceutical companies to innovate and introduce new therapeutic drugs that address symptom management and disease modification. Increasing awareness and diagnosis of Parkinson's disease, coupled with a rising geriatric population, further catalyze market expansion. As investments in novel drug development grow, the market is poised for sustained growth, reflecting the increasing commitment to improving patient outcomes and enhancing the quality of life for those affected by Parkinson's disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Parkinson's Disease Drug Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Decarboxylase Inhibitors
• Dopamine Agonists
• COMT Inhibitors
• MAO-B Inhibitors
• Others

Global Parkinson's Disease Drug Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection
• Transdermal

Global Parkinson's Disease Drug Market Size by Age & CAGR (2025-2032)

• Market Overview
• < 50 Years
• >50 Years

Global Parkinson's Disease Drug Market Size & CAGR (2025-2032)

• North America (Drug Class, Administration, Age)
  • US
  • Canada
• Europe (Drug Class, Administration, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Administration, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Administration, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Administration, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Supernus Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company OvervSiew
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luye Pharma Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revance Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations